Abliva Overview
- Year Founded
-
2000

- Status
-
Public
- Employees
-
6

- Stock Symbol
-
ABLI

- Investments
-
2
- Share Price
-
$0.04
- (As of Friday Closing)
Abliva General Information
Description
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.
Contact Information
Website
www.abliva.comCorporate Office
- Scheeletorget 1
- 223 81 Lund
- Sweden
Corporate Office
- Scheeletorget 1
- 223 81 Lund
- Sweden
Abliva Stock Performance
As of 14-Feb-2025, Abliva’s stock price is $0.04. Its current market cap is $67.5M with 1.61B shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.04 | $0.04 | $0.01 - $0.04 | $67.5M | 1.61B | 6.89M |
Abliva Financials Summary
As of 30-Sep-2024, Abliva has a trailing 12-month revenue of $13K.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 22,107 | 20,584 | 11,477 | 19,426 |
Revenue | 13 | 13 | 3 | 18 |
EBITDA | (8,335) | (8,908) | (7,914) | (14,069) |
Net Income | (8,411) | (8,986) | (8,404) | (14,380) |
Total Assets | 9,599 | 8,755 | 17,622 | 6,510 |
Total Debt | 0 | 0 | 0 | 0 |
Abliva Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Abliva Comparisons
Industry
Financing
Details
Abliva Competitors (34)
One of Abliva’s 34 competitors is Xenetic Bioscience, a Corporation company based in Framingham, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Xenetic Bioscience | Corporation | Framingham, MA | ||||
ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
Genfit | Formerly VC-backed | Loos, France | ||||
Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Abliva Patents
Abliva Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022277623-A1 | Kl1333 for use in medicine | Pending | 19-May-2021 | ||
CA-3218015-A1 | Kl1333 for use in medicine | Pending | 19-May-2021 | ||
EP-4340831-A1 | Kl1333 for use in medicine | Pending | 19-May-2021 | ||
US-20240238255-A1 | Kl1333 for use in medicine | Pending | 19-May-2021 | ||
US-11565998-B2 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | Active | 19-Jun-2019 | C07C327/30 |
Abliva Signals
Abliva Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Abliva Investments & Acquisitions (2)
Abliva’s most recent deal was a Early Stage VC with Isomerase for . The deal was made on 15-Aug-2016.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Isomerase | 15-Aug-2016 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
Biotica Technology | 11-Mar-2013 | Merger/Acquisition | Biotechnology |
Abliva ESG
Risk Overview
Risk Rating
Updated February, 01, 2024
29.22 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Abliva FAQs
-
When was Abliva founded?
Abliva was founded in 2000.
-
Where is Abliva headquartered?
Abliva is headquartered in Lund, Sweden.
-
What is the size of Abliva?
Abliva has 6 total employees.
-
What industry is Abliva in?
Abliva’s primary industry is Pharmaceuticals.
-
Is Abliva a private or public company?
Abliva is a Public company.
-
What is Abliva’s stock symbol?
The ticker symbol for Abliva is ABLI.
-
What is the current stock price of Abliva?
As of 14-Feb-2025 the stock price of Abliva is $0.04.
-
What is the current market cap of Abliva?
The current market capitalization of Abliva is $67.5M.
-
What is Abliva’s current revenue?
The trailing twelve month revenue for Abliva is $13K.
-
Who are Abliva’s competitors?
Xenetic Bioscience, ACADIA Pharmaceuticals, Agios Pharmaceuticals, Genfit, and Mission Therapeutics are some of the 34 competitors of Abliva.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »